Acquired Point Mutations of TKD Are Responsible for Sorafenib Resistance in FLT3-ITD Mutant AML

被引：0
|
作者：
Zhang, Weiguo [1 ]
Konopleva, Marina [1 ]
Jacamo, Rodrigo O. [1 ]
Borthakur, Gautam
Chen, Wenjing
Cortes, Jorge E.
Ravandi, Farhad
Andreeff, Michael [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
LEUKEMIA;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1495 / 1495
页数：1
相关论文
共 50 条
  • [41] A Comparative Study of Various FLT3-ITD Mutations
    Nordigarden, A.
    Halvarsson, C.
    Tang, Y. J. T.
    Jonsson, J. I.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S121 - S121
  • [42] SRC is a signaling mediator in FLT3-ITD-but not in FLT3-TKD-positive AML
    Leischner, Hannes
    Albers, Corinna
    Grundler, Rebekka
    Razumovskaya, Elena
    Spiekermann, Karsten
    Bohlander, Stefan
    Ronnstrand, Lars
    Goetze, Katharina
    Peschel, Christian
    Duyster, Justus
    BLOOD, 2012, 119 (17) : 4026 - 4033
  • [43] VARIANT FLT3 MUTATIONS CAN BE ERADICATED BY CYTARABINE/ANTHRACYCLINE/CRENOLANIB INDUCTION IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3 (ITD/TKD) MUTANT AML
    Wang, E.
    Stone, R.
    Collins, R.
    Agrawal, T.
    Urity, V.
    Tallman, M.
    HAEMATOLOGICA, 2017, 102 : 212 - 212
  • [44] LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway
    Huang, Amin
    Zeng, Peiting
    Li, Yinguang
    Lu, Wenhua
    Lai, Yaoming
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [45] Decitabine and sorafenib therapy in FLT3-ITD mutant acute myeloid leukemia- A case series
    Muppidi, Monica R.
    Griffiths, Elizabeth A.
    Thompson, James E.
    Ford, Laurie A.
    Freyer, Craig W.
    Wetzler, Meir
    Wang, Eunice S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S187 - S187
  • [46] Role of Enhanced Autophagy in Resistance of FLT3-ITD AML Stem Cells to FLT3 TKI Treatment
    Qiu, Shaowei
    Paterson, Andrew J.
    Abraham, Ajay
    He, Jianbo
    Shah, Mansi
    Agarwal, Puneet
    Mullen, Amanda K.
    Li, Hui
    Harris, Mason W.
    Anderson, Nicholas R.
    Bhatia, Ravi
    BLOOD, 2018, 132
  • [47] Characteristics of FLT3-ITD and Efficacy of Sorafenib Treatment in Pediatric AML: A Report from AML-BFM Study Group
    Antoniou, Evangelia
    Puschnig, Annika
    Hoffmeister, Lina Marie
    Awada, Amani
    Von Neuhoff, Nils
    Schneider, Markus
    Reinhardt, Dirk
    Niktoreh, Naghmeh
    BLOOD, 2023, 142
  • [48] Upregulation of Bcl-2 Confers Resistance to FLT3 Inhibition in FLT3ITD AML with Secondary Acquired Mutations
    Yamatani, Kotoko
    Tabe, Yoko
    Saito, Kaori
    Yang, Haeun
    Murakami-Tonami, Yuko
    Suzuki, Koya
    Zhang, Weiguo
    Kinjo, Sonoko
    Ikeo, Kazuho
    Mogushi, Kaoru
    Hosoya, Masaki
    Yamaguchi, Shigeo
    Harada, Hironori
    Miida, Takashi
    Shah, Neil P.
    Konopleva, Marina Y.
    Hayashizaki, Yoshihide
    Andreeff, Michael
    BLOOD, 2018, 132
  • [49] Sorafenib plus 5-azacytidine (AZA) in older untreated FLT3-ITD mutated AML.
    Ohanian, Maro
    Garcia-Manero, Guillermo
    Levis, Mark J.
    Jabbour, Elias
    Daver, Naval Guastad
    Borthakur, Gautam
    Kadia, Tapan M.
    Brandt, Mark
    Pierce, Sherry
    Burger, Jan Andreas
    Richie, Mary Ann
    Patel, Keyur
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT
    Rautenberg, Christina
    Nachtkamp, Kathrin
    Dienst, Ariane
    Schmidt, Pia Verena
    Heyn, Claudia
    Kondakci, Mustafa
    Germing, Ulrich
    Haas, Rainer
    Kobbe, Guido
    Schroeder, Thomas
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (04) : 348 - 354
12345